PDF(Pubmed)
Abstract：
UNASSIGNED: Since the introduction of drug-eluting beads (DEB), the result comparing transarterial chemoembolization (TACE) using lipiodol, also called conventional transarterial chemoembolization (c-TACE), and DEB-TACE shows considerable controversy. The objective of this study was to compare the safety and efficacy of c-TACE and DEB-TACE to treat unresectable hepatocellular carcinoma (uHCC).
UNASSIGNED: This retrospective study used propensity score matching (PSM) analysis to analyze clinical data from 113 cases of primary hepatocellular carcinoma (HCC) treated at our hospital from September 2016 to July 2021. The safety and efficacy of the two treatment modalities were analyzed after 1:1 matching. The primary endpoint was progression-free survival (PFS); the secondary endpoints included overall survival (OS), disease control rates (DCRs), and objective response rates (ORRs) at 1, 3, 6, and 12 months, and postoperative complications.
UNASSIGNED: Twenty-nine patients underwent DEB-TACE and 84 received c-TACE; 28 pairs of patients were eventually matched. After matching, baseline characteristics between groups were comparable. The median PFS of the DEB-TACE group was 10 months compared to 6 months in the c-TACE group (P=0.002). The median OS was 23 months in the DEB-TACE group vs. 14 months in the c-TACE group, but the difference was not statistically significant (P=0.265). The ORR at 1, 3, 6, and 12 months in the DEB-TACE group (69%, 78%, 60%, and 52%) were significantly higher than those in the c-TACE group (39%, 39%, 26%, and 8%) (P<0.05). The DCR at postoperative 3 months was significantly higher in the DEB-TACE group (95%) (P<0.05). There was one case of postoperative liver abscess in the DEB-TACE group, and the patient recovered well after drainage. No serious complications occurred.
UNASSIGNED: Compared to c-TACE, DEB-TACE prolonged PFS and exhibited better short-term ORR with a similar level of safety. However, there was no significant advantage in terms of OS.
UNASSIGNED: This retrospective study used propensity score matching (PSM) analysis to analyze clinical data from 113 cases of primary hepatocellular carcinoma (HCC) treated at our hospital from September 2016 to July 2021. The safety and efficacy of the two treatment modalities were analyzed after 1:1 matching. The primary endpoint was progression-free survival (PFS); the secondary endpoints included overall survival (OS), disease control rates (DCRs), and objective response rates (ORRs) at 1, 3, 6, and 12 months, and postoperative complications.
UNASSIGNED: Twenty-nine patients underwent DEB-TACE and 84 received c-TACE; 28 pairs of patients were eventually matched. After matching, baseline characteristics between groups were comparable. The median PFS of the DEB-TACE group was 10 months compared to 6 months in the c-TACE group (P=0.002). The median OS was 23 months in the DEB-TACE group vs. 14 months in the c-TACE group, but the difference was not statistically significant (P=0.265). The ORR at 1, 3, 6, and 12 months in the DEB-TACE group (69%, 78%, 60%, and 52%) were significantly higher than those in the c-TACE group (39%, 39%, 26%, and 8%) (P<0.05). The DCR at postoperative 3 months was significantly higher in the DEB-TACE group (95%) (P<0.05). There was one case of postoperative liver abscess in the DEB-TACE group, and the patient recovered well after drainage. No serious complications occurred.
UNASSIGNED: Compared to c-TACE, DEB-TACE prolonged PFS and exhibited better short-term ORR with a similar level of safety. However, there was no significant advantage in terms of OS.
摘要：
■由于引入了药物洗脱珠（DEB），比较使用碘油的经动脉化疗栓塞（TACE）的结果，也称为常规经动脉化疗栓塞（c-TACE），和DEB-TACE显示相当大的争议。这项研究的目的是比较c-TACE和DEB-TACE治疗不可切除的肝细胞癌（uHCC）的安全性和有效性。
■这项回顾性研究使用倾向评分匹配（PSM）分析，分析了2016年9月至2021年7月在我院治疗的113例原发性肝细胞癌（HCC）的临床数据。1:1匹配后分析两种治疗方式的安全性和有效性。主要终点是无进展生存期（PFS）；次要终点包括总生存期（OS），疾病控制率（DCRs），和1、3、6和12个月的客观反应率(ORR)，术后并发症。
■29例患者接受DEB-TACE，84例接受c-TACE；28对患者最终配对。匹配后,组间基线特征具有可比性.DEB-TACE组的中位PFS为10个月，而c-TACE组为6个月（P=0.002）。DEB-TACE组的中位OS为23个月。c-TACE组14个月，但差异无统计学意义(P=0.265)。DEB-TACE组1、3、6和12个月时的ORR（69%，78%,60%,和52%)显著高于c-TACE组(39%,39%,26%,8%)(P<0.05)。DEB-TACE组术后3个月DCR明显高于对照组(95%)(P<0.05)。DEB-TACE组有1例术后肝脓肿,引流后患者恢复良好。无严重并发症发生。
■与c-TACE相比，DEB-TACE延长了PFS，并表现出更好的短期ORR，安全性水平相似。然而,在操作系统方面没有显著优势。
■这项回顾性研究使用倾向评分匹配（PSM）分析，分析了2016年9月至2021年7月在我院治疗的113例原发性肝细胞癌（HCC）的临床数据。1:1匹配后分析两种治疗方式的安全性和有效性。主要终点是无进展生存期（PFS）；次要终点包括总生存期（OS），疾病控制率（DCRs），和1、3、6和12个月的客观反应率(ORR)，术后并发症。
■29例患者接受DEB-TACE，84例接受c-TACE；28对患者最终配对。匹配后,组间基线特征具有可比性.DEB-TACE组的中位PFS为10个月，而c-TACE组为6个月（P=0.002）。DEB-TACE组的中位OS为23个月。c-TACE组14个月，但差异无统计学意义(P=0.265)。DEB-TACE组1、3、6和12个月时的ORR（69%，78%,60%,和52%)显著高于c-TACE组(39%,39%,26%,8%)(P<0.05)。DEB-TACE组术后3个月DCR明显高于对照组(95%)(P<0.05)。DEB-TACE组有1例术后肝脓肿,引流后患者恢复良好。无严重并发症发生。
■与c-TACE相比，DEB-TACE延长了PFS，并表现出更好的短期ORR，安全性水平相似。然而,在操作系统方面没有显著优势。
